Project description
Subcutaneous administration of immunotherapy drugs
Intravenous (IV) administration offers rapid and precise delivery of medications or fluids directly into the bloodstream, ensuring quick onset of action and accurate dosing, which is particularly beneficial for patients unable to take oral medications. However, IVs come with risks, including potential infections, vein damage or irritation, and the possibility of medication leakage. Although subcutaneous (SC) administration is seen as a promising alternative, development of biological drugs and cellular therapies suitable for SC use is limited. Funded by the European Research Council, the Sub-NK project aims to develop functionalised hydrogels for controlled release of modified natural killer cells, paving the way towards establishing the SC route for cancer immunotherapy.
Objective
This PoC project seeks to develop a simple-to-implement self-assembled and injectable hydrogel material for the controlled co-delivery of our simili-CAR NK cells and stimulatory cytokines to improves treatment of both solid and liquid tumors. Similar to biologics delivery where monoclonal antibodies (mAbs) are commonly administered by IV infusion due to regulatory criteria favoring such route which had limited confounding factors, the IV administration remains responsible for some over costs and clinical challenges including the need for dedicated infusion facilities, aseptic preparation of required infusion batches, extended infusion times, potential difficulties and risks with IV catheter. The subcutaneous (SC) administration is deemed to overcome many of these challenges and might appear as an attractive alternative to the IV administration. In addition, the SC route used for mAb administration was received with an overwhelming preference according to patients despite limited and reversible local adverse events induced by the rHuPH20. Alternative solutions are being evaluated through clinical trials such as the direct SC injection of mAbs without recombinant human hyaluronidase or using novel enzymes but none are currently being clinically-developed for cellular therapies. Moreover, those alternative SC methods induced large pharmacokinetic heterogeneity between patients confirming the need to develop novel alternative approaches to accelerate the development of SC mAbs formulation. Hence, in parallel to the biological approach, chemistry-based approaches, such as hydrogels have been proposed. However, to date, none of them successfully managed to be translated to the clinic; this can be explained by the absence of full biodegradability after injection or/and potential poor biocompatibility inducing inflammatory responses. Here, we sought to develop a novel formulation of functionalized-chitosans for controlled release of modified NK cells.
Keywords
Programme(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Funding Scheme
HORIZON-ERC-POC - HORIZON ERC Proof of Concept GrantsHost institution
67065 Strasbourg
France